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Edited by Irmgard SinningAbstract We have investigated the eﬀect of the sulfhydryl-reac-
tive reagent, methyl thiosulfonate ethylammonium (MTSEA), on
ligand binding to the human melanocortin-4 (MC4) receptor sta-
bly expressed in HEK-293 cells. MTSEA inhibited binding of the
agonist, 125I-NDPa-MSH, and the antagonist, 125I-SHU9119,
in a concentration-dependent manner. Pre-incubation of cells
with either the agonist or antagonist protected from subsequent
MTSEA inhibition of radioligand binding. Mutation of Cys130
in transmembrane helix 3 to alanine, whilst not aﬀecting ligand
binding, led to a complete loss of the inhibitory eﬀect of
MTSEA. Since other types of sulfhydryl-reactive reagents had
no eﬀect on ligand binding, we conclude that covalent modiﬁca-
tion of Cys130 by MTSEA disrupts ligand binding by neutralis-
ing a close-by negative charge, most likely on Asp126.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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G protein-coupled receptor1. Introduction
The melanocortins (adrenocorticotropic hormone, a-, b-c-
melanocyte stimulating hormone [MSH]) are short biologically
active peptides, of related sequence, derived from tissue-spe-
ciﬁc cleavage of a precursor protein, proopiomelanocortin
and all contain the conserved core sequence, -His-Phe-Arg-
Trp-, which is crucial for their biological activity. Their biolog-
ical eﬀects are mediated by a group of membrane receptors
(the melanocortin (MC) receptors) which belong to the G pro-Abbreviations: GPCR, G protein-coupled receptor; IAA, iodoaceta-
mide; MC, melanocortin; a-MSH, a-melanocyte-stimulating hormone;
MTS, methane thiosulfonate; MTSEA, MTS ethylammonium; NEM,
N-ethyl maleimide; NDPa-MSH, [Nle4, D-Phe7]a-MSH; SHU9119,
acetyl-Nle4-cyclo[Asp5, D-2-Nal7, Lys10]a-MSH(4-10) amide; TM,
transmembrane
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abundant family of membrane receptor proteins encoded by
the eukaryotic genome. GPCRs are characterised by the pres-
ence of seven membrane spanning a-helices and are subdivided
into several families according to function and amino acid se-
quence similarity. The MC receptors belong to family A, the
rhodopsin-like family, and to date ﬁve MC receptors (MC1–
MC5) have been characterised and cloned. They share a high
degree of sequence identity and stimulate the cyclic AMP sec-
ond messenger signal transduction pathway. However, the MC
receptor subtypes are localised in diﬀerent tissues and have
speciﬁc physiological roles. These include regulation of pig-
mentation (MC1 receptor), glucocorticoneogenesis (MC2
receptor), energy homeostasis and appetite (MC3 and MC4
receptors) and exocrine gland secretion (MC5 receptor) [1–3].
There is a considerable body of evidence for MC4 receptor
involvement in the control of food intake and energy balance
both in rodents and in humans. MC4 receptors are especially
abundant in the hypothalamus, the major centre within the
brain involved in the control of energy homeostasis [4]. MC4
receptor knockout mice display hyperphagia and severe obes-
ity [5] and transgenic mice that overexpress AgRP (an endog-
enous antagonist of MC1 and MC4 receptors) display an obese
phenotype [6]. In rats, administration of the MC4 receptor
agonist, MTII, reduces food intake and body weight [7],
whereas administration of the highly selective MC4 receptor
antagonist, HS014, induces sustained feeding and obesity [8].
In humans, administration of MC4 receptor agonists de-
creased body fat levels [9] and several native point mutations
in the MC4 receptor have been linked to obesity [10]. Conse-
quently, the MC4 receptor represents a major potential phar-
macological target for the treatment of obesity.
Using the classical mutagenic approach, several recent pub-
lications have highlighted putative ligand-binding residues in
the MC receptors. Brieﬂy, two crucial types of interactions
have been proposed: ﬁrstly, an ionic interaction between the
positively charged Arg8 of NDPa-MSH ([Nle4, D-Phe7]a-
MSH) and one or more acidic residues on the receptor; and
secondly, a putative hydrophobic cluster involving the
side-chains of Phe7 and Trp9 in the ligand and hydrophobic
side-chains on transmembrane helices (TMs) 4, 5 and 6 in
the receptor [11,12]. In human MC4 receptors, alanine substi-
tution of Asp122 or Asp126 in TM3 resulted in decreases in
aﬃnity for NDPa-MSH of 5- and 1000-fold, respectively
[11]. On the basis of the similar aﬃnities of WT- and Asp122Alaation of European Biochemical Societies.
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molecular interaction between Arg8 of the ligand and
Asp122 has been proposed [11]. However, since NDPa-MSH
was observed to have a greater binding aﬃnity than Nle8-
NDPa-MSH at the Asp122Ala mutant receptor, it seems likely
that the ligand Arg8 residue interacts with one or more recep-
tor residues in addition to Asp122. Potentially, these could in-
clude any of ﬁve other acidic residues within the TM helices
which, when substituted, also reduce ligand binding.
The use of highly speciﬁc cysteine-modifying reagents has
proved an important tool in studies of structure/function rela-
tionships in a number of membrane proteins including ion
channels, transporters and receptors [13–18]. An important ap-
proach is the substituted-cysteine-accessibility method in
which introduced cysteines are tested for their susceptibility
to modiﬁcation by water-soluble methanethiosulfonate
(MTS) reagents to determine buried, exposed and/or function-
ally important positions. The most commonly used water-
soluble MTS reagent is the positively charged analogue,
MTS ethylammonium (MTSEA), which converts the neutral
cysteine side-chain to a positively charged group resembling
a lysine side-chain. This reagent has been used to demonstrate
the presence of a water-accessible cysteine within the binding-
site crevice of the human dopamine D2 receptor [19] and also
demonstrated the rotation of TM6 (upon receptor activation)
by the appearance of an MTSEA-accessible cysteine in a con-
stitutively active mutant of the b2-adrenergic receptor not
accessible in the wild-type receptor [20]. The eﬀect of MTSEA
on ligand binding, in conjunction with site-directed mutagene-
sis, has also been used to deﬁne intramolecular contacts in the
neurokinin-2 tachykinin receptor [21]. Here, we describe exper-
iments on the eﬀect of MTS reagents on ligand binding to
the human MC4 receptor and identify particularly sensitive
positions.2. Materials and methods
2.1. Materials
The expression vector, pcDNA3MC4-R, containing cDNA for the
human MC4 receptor was provided by Knoll Pharmaceuticals (Not-
tingham). 125I-NDPa-MSH and 125I-acetyl-Nle4-cyclo[Asp5, D-2-Nal7,
Lys10]a-MSH(4-10) amide (SHU9119) were obtained from Perkin El-
mer Life Sciences (Boston, MA) and MTS reagents from Toronto Re-
search Chemicals Inc. (Ontario, Canada). Non-radioactive peptides
were purchased from Bachem (St. Helens, UK), cell culture reagents
from Invitrogen (Paisley, UK) and protease inhibitor cocktail tablets
from Roche (Lewes, UK). Oligonucleotide primers were synthesised
by Sigma-Genosys Ltd. (Pampisford, UK).2.2. Mutagenesis
Point mutations were introduced into the MC4 receptor sequence
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene,
Amsterdam, The Netherlands) and the pcDNA3MC4-R vector as tem-
plate. Correct DNA sequences were conﬁrmed by ABI PRISM Dye
Terminator Cycle Sequencing (Perkin–Elmer).2.3. Receptor expression in HEK-293 cells
Human embryonic kidney cells (HEK-293) were maintained in Dul-
beccos modiﬁed Eagles medium (DMEM) supplemented with 10%
foetal calf serum, 100 U/ml penicillin, 100 lg/ml streptomycin and
Glutamax (Invitrogen). Cells were transfected with pcDNA3 vectors
containing the wild type and mutant MC4 receptor sequences using
SuperFect Transfection Reagent (Qiagen, Crawley, UK) and stableclones selected with the antibiotic, geneticin sulfate (G418), essentially
as previously described [22]. In all cases, several clones of each mutant
were tested and the highest binding clones selected for further analysis.
2.4. Radioligand binding assays
Radioligand binding was carried out using intact HEK-293 cells sus-
pended in a binding buﬀer comprising serum-free DMEM supple-
mented with 0.2% (w/v) bovine serum albumin and one protease
inhibitor cocktail tablet per 50 ml. Typically, 125I-SHU9119 binding
was carried out in a ﬁnal volume of 0.2 ml binding buﬀer containing
30 pM 125I-SHU9119 and 2 · 105 cells for 45 min at 22 C. Non-spe-
ciﬁc binding was deﬁned as the level of binding detected in the presence
of 1 lM unlabelled SHU9119. Cell-bound radioactivity was recovered
by rapid vacuum ﬁltration through glass-ﬁbre paper (Whatman GF/B
ﬁlters pre-soaked in 1% w/v polyethyleneimine) using a Brandel cell
harvester and unbound ligand removed by three washes with 3 ml
ice-cold PBS. Filter-bound radioactivity was measured in a gamma
counter (RiaStar 5405 counter; Packard, Pangbourne, UK). 125I-
NDPa-MSH binding was carried out in a similar manner except that
the ﬁnal assay volume was 0.1 ml and 125I-NDPa-MSH was used at
140 pM. Non-speciﬁc binding was deﬁned as the level of binding de-
tected in the presence of 1 lM unlabelled NDPa-MSH.
2.5. MTSEA treatment of cells
Cells were treated with MTSEA for 10 min at 22 C in 0.25 ml bind-
ing buﬀer and then washed by addition of 1 ml binding buﬀer followed
by centrifugation in a microfuge (5000 · g, 2 min) and resuspension of
the cell pellets in fresh binding buﬀer.
2.6. cAMP accumulation assays
cAMP accumulation in HEK-293 cells was determined by the meth-
od of Salomon et al. [22] as reported previously. Brieﬂy, [3H]adenine
pre-loaded cells on 6-well plates were stimulated with various concen-
trations of agonist for 12 min at 37 C and reactions terminated by
addition of ice-cold 5% (w/v) TCA containing an internal column stan-
dard of [14C]cAMP. Cyclic AMP was then isolated from the TCA ex-
tracts by sequential column chromatography on Dowex 50W-X8 and
alumina resins. 3H and 14C dpm were determined by dual isotope li-
quid scintillation counting and the cell-derived [3H]cAMP dpm ad-
justed for the recovery of the [14C]cAMP internal standard from
individual columns.
2.7. Data analysis
All measurements (except where stated) were made in triplicate in
three independent experiments and values quoted and depicted graph-
ically are the means of the independent determinations with the SEM.
In competition binding experiments, counts were normalised to the
maximal speciﬁc binding within each data set and the IC50 values cal-
culated with a single site-binding model ﬁtted using a non-linear
regression analysis with the aid of GraphPad PRISM 3.0 software
(San Diego, CA). In a similar fashion, EC50 values were calculated
from the ﬁt of sigmoidal concentration–response curves. pIC50 refers
to logIC50 and pEC50 refers to logEC50. The signiﬁcance of diﬀer-
ences between values was determined by the comparison of mean val-
ues using a two tailed unpaired Students t test.
2.8. Molecular modelling
The three-dimensional structure of rhodopsin [25] was used as a tem-
plate on which a model of the 7 TM helices of the MC4 receptor was
built by replacing equivalent side-chains using SYBYL v6.3. The mod-
el was energy minimised using 2000 steps of conjugated gradient opti-
misation with the Tripos forceﬁeld.3. Results
MTSEA, applied extracellularly to cells expressing wild-type
MC4 receptors, inhibited binding of both the agonist, 125I-
NDPa-MSH and the antagonist, 125I-SHU9119 in a similar
concentration-dependent manner (Figs. 1A and B). The bind-
ing of both ligands was particularly altered upon increasing the
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Fig. 2. Protection of MTSEA inhibition of 125I-SHU9119 binding to
the MC4 receptor by co-incubation with peptide ligands. Cells stably
expressing wild type MC4 receptors were incubated with the indicated
concentrations of either NDPa-MSH or SHU9119 for 30 min at 22 C.
Each sample was then divided into two aliquots, to which binding
buﬀer was added to one and MTSEA added to a ﬁnal concentration of
2.5 mM to the other and the incubation continued for a further 10 min.
Cells were pelleted in a microfuge and resuspended in 1 ml of isotonic
glycine buﬀer, pH 3.0 (25 mM glycine, 137 mM NaCl, 2 mM CaCl2, 1
mMMgSO4 and 0.2% (w/v) BSA, pH 3.0), and incubated for 20 min at
22 C. This treatment had previously been found to eﬃciently remove
radioligands from the MC4 receptor. Cells were then spun down again
and washed further in 0.5 ml binding buﬀer and then assayed for 125I-
SHU9119 binding. For each concentration of protecting peptide, 100%
speciﬁc binding is deﬁned as the level of binding observed in samples
not treated with MTSEA.
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Fig. 1. The eﬀect of MTSEA on 125I-NDPa-MSH and 125I-SHU9119
binding to wild type MC4 receptors stably expressed in HEK-293 cells.
Cells were treated with the indicated concentrations of MTSEA for 10
min, washed and then assayed for, (A) 125I-NDPa-MSH and (B) 125I-
SHU9119 binding. Percent speciﬁc binding retained refers to the level
of speciﬁc binding after MTSEA treatment normalised to the level of
speciﬁc binding in untreated cells. 100% speciﬁc binding is deﬁned as
total binding minus non-speciﬁc binding (binding in the presence of 1
lM unlabelled peptide) in untreated cells.
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occurring between these concentrations. At the highest concen-
tration, 10 mM MTSEA produced an almost complete block
of both agonist and antagonist binding. The inhibitory eﬀect
of MTSEA on 125I-SHU9119 binding was reduced by separate
co-incubation with either NDPa-MSH or SHU9119 in a con-
centration-dependent manner (Fig. 2). At a concentration of
200 nM, both ligands achieved almost complete protection
from the action of MTSEA. SHU9119 protected more eﬀec-
tively than NDPa-MSH, consistent with their relative aﬃnities
for the MC4 receptor [23,24].
The above observations indicate the presence of a water-
accessible cysteine residue(s) within or close to the peptide
ligand-binding site. The MC4 receptor contains 15 cysteines
but when a model of the MC4 receptor sequence was built
based on the structure of bovine rhodopsin [25], seven of these
occupy positions that are unlikely to be accessible to water-
soluble reagents added extracellularly (Fig. 3). Cys84(TM2),
Cys138(TM3) and Cys172(TM4) are considered to be too close
to the interior of the protein, Cys293(TM7) is orientated to-
wards the membrane lipid and Cys318, Cys319 and Cys326
are located within the intracellular C-terminal domain. In or-
der to identify the MTSEA-susceptible cysteine, we mutated
the remaining eight cysteine residues individually to alanine.
These were Cys40 (N-terminal domain), Cys130 (TM3),Cys177 (TM4), Cys196 (TM5) and Cys257 (TM6) and three
within the third extracellular loop, Cys271, Cys277 and
Cys279 (Fig. 3). When expressed in HEK-293 cells, these eight
individual Cys/Ala MC4 receptor mutants were found to have
no eﬀect on either antagonist binding or receptor activation as
assessed by 125I-SHU9119 binding and NDPa-MSH induced
cAMP accumulation, respectively (Table 1). The eﬀect of
MTSEA on 125I-SHU9119 binding to these mutants was also
tested (Fig. 4). At both 1 and 2.5 mM MTSEA, binding to
the Cys130Ala mutant was unaﬀected, whereas the other seven
mutants behaved similarly to wild-type MC4 receptors in that
speciﬁc binding was reduced to 50–75% for 1 mM and 20–50%
for 2.5 mM of the binding observed in untreated samples.
The eﬀect of other cysteine-reactive reagents on 125I-SHU9119
binding to wild-type MC4 receptors was also examined
(Fig. 5A). At a concentration of 10 mM, MTSPA (positively
charged), MTSES (negatively charged), N-ethyl maleimide
(NEM) and iodoacetamide (IAA) essentially had no eﬀect on
ligand binding, whereas in the same experiments 10 mM
MTSEA inhibited binding by more than 95%. To determine
whether or not these reagents reactedwith theMTSEA-sensitive
cysteine, treated cells were subjected to an additional treatment
with MTSEA. In all cases, the additional MTSEA treatment
resulted in a loss ofmore than 90%of speciﬁc binding, indicating
that MTSPA, MTSES, NEM and IAA do not react with the
MTSEA-sensitive cysteine.4. Discussion
Our data show that mutation of eight cysteine residues
individually to alanine in the human MC4 receptor had no
Fig. 3. Two-dimensional snake representation of the human MC4 receptor showing the approximate extent of the seven transmembrane helices and
the position of all 15 cysteine residues. The eight cysteine residues that were individually mutated to alanine in this study are shown as white letters on
a black background. The remaining seven cysteine residues are shown as black letters on a grey background. Further details are given in the text.
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these residues make a crucial contribution to the binding of li-
gands. Some of these cysteine residues have been mutated by
others and also found to have no eﬀect on binding. These in-
clude Cys130 and 196 in the human MC4 receptor [11],
Cys122 in the mouse MC4 receptor (equivalent to Cys130 in
human MC4 receptor) [12] and in the mouse MC1 receptor,
mutation of cysteines equivalent to the MC4 receptor cysteines
40, 130, 196 and 277 [26]. Mutation of the conserved cysteineTable 1
Antagonist binding and agonist activation properties of wild type and
mutant MC4 receptors
Receptor mutation SHU9119 bindinga
pIC50
NDPa-MSH activationb
pEC50
WT 9.20 ± 0.06 (0.63) 7.70 ± 0.24 (20.0)
C40A 9.00 ± 0.07 (1.00) 7.89 ± 0.24 (12.8)
C130A 9.05 ± 0.03 (0.89) 7.38 ± 0.03 (41.7)
C177A 9.18 ± 0.07 (0.66) 7.55 ± 0.12 (28.2)
C196A 9.37 ± 0.06 (0.43) 7.76 ± 0.11 (17.4)
C257A 9.16 ± 0.19 (0.69) 7.64 ± 0.11 (22.9)
C271A 9.41 ± 0.22 (0.39) 7.37 ± 0.15 (42.7)
C277A 9.31 ± 0.06 (0.49) 7.45 ± 0.11 (35.5)
C279A 9.39 ± 0.12 (0.41) 7.73 ± 0.07 (18.6)
Competition binding assays and agonist concentration response curves
were performed as described in the methods section. (a) For SHU9119
binding, n = 3 except for C271A (n = 2), C277A (n = 4) and C279A
(n = 4). Data are expressed as pIC50 ± SEM followed by, in brackets,
IC50 values in nM. (b) For NDPa-MSH activation, n = 3 except for
C130A (n = 2), C277A (n = 4) and C279A (n = 2). Potency values are
expressed as pEC50 ± SEM followed by, in brackets, EC50 values in
nM. Values for all mutants for antagonist binding and receptor acti-
vation were not signiﬁcantly diﬀerent from the values for the wild type
MC4 receptor (P > 0.1).in the N-terminal domain of the MC1 receptor from diﬀerent
species (Cys40 in human MC4 receptor) resulted in diﬀerent
outcomes and hence its role remains to be clariﬁed [26,27].
It is clear that the three cysteines in extracellular loop 3 (cys-
teines 271, 277 and 279 in the human MC4 receptor) are con-
served amongst all MC receptor subtypes and in the MC1
receptor the outer two of these are postulated to form a disul-
ﬁde bond, which is crucial for receptor function [26]. It is sur-
prising, therefore, that here, for the MC4 receptor we observed
no eﬀect of substituting any of the cysteines in the third extra-
cellular loop. This may indicate the lack of a similar disulﬁde
bond in the MC4 receptor or that, if present, such a bond is
not important for ligand binding. Clearly, there are important
diﬀerences in the eﬀects of cysteine residue substitution be-
tween diﬀerent MC receptor subtypes and also species diﬀer-
ences for similar subtypes which have yet to be fully
understood.
We have demonstrated that the positively charged cysteine-
modifying reagent, MTSEA, blocks ligand binding in the hu-
man MC4 receptor by a speciﬁc reaction with Cys130 found
close to the middle of TM3. Binding of the agonist, NDPa-
MSH and the antagonist, SHU9119 was similarly inhibited
by MTSEA in a concentration-dependent manner. Of the ﬁf-
teen cysteine residues present in the MC4 receptor, only eight
occupy positions that could potentially be involved in ligand
binding. When each of these was individually mutated to ala-
nine, seven retained sensitivity to MTSEA, whereas the Cy-
s130Ala mutant receptor was no longer aﬀected by MTSEA
(Fig. 4). This is similar to observations made for the human
dopamine D2 receptor in which Cys118, also in TM3, was
modiﬁed by MTSEA causing inhibition of antagonist binding
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Fig. 4. Eﬀect of MTSEA pre-treatment on 125I-SHU9119 binding to
wild type and mutant MC4 receptors. Cells expressing wild type and
mutant MC4 receptors were treated with either 1 or 2.5 mM MTSEA
for 10 min at 22 C, washed and then assayed for speciﬁc 125I-
SHU9119 binding. The values for the C130A mutant were signiﬁcantly
diﬀerent from the wild type value (for 1mM MTSEA, *P < 0.025 and
for 2.5 mM MTSEA, **P < 0.002).
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Fig. 5. Eﬀect of various SH-reagents on 125I-SHU9119 binding to wild
type MC4 receptors. (A) Cells expressing wild type MC4 receptors
were treated with the SH-reagents shown (all at 10 mM) for 10 min at
22 C, washed and then assayed for speciﬁc 125I-SHU9119 binding.
The level of binding obtained was related to the level of binding in
untreated cells (100% binding). (B) Cells expressing wild type MC4
receptors were treated with the SH-reagents shown for 10 min at 22 C,
washed and then all samples treated for a further 10 min with 10 mM
MTSEA. After a further washing step, cells were assayed for 125I-
SHU9119 binding. The level of binding obtained was related to the
level of binding in untreated cells (100% binding).
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quences demonstrates that the MTSEA-sensitive cysteines
are located in diﬀerent positions, Cys118 in the D2 receptor
being one a-helical turn deeper into the lipid bilayer than
Cys130 in the MC4 receptor.
Mutation of Cys130 to alanine had no signiﬁcant eﬀect on
agonist or antagonist binding (Table 1), suggesting that there
is no direct interaction between Cys130 and either ligand and
is not itself critical for ligand binding. However, since pre-incu-
bation with agonist or antagonist reduced the inhibitory eﬀect
of MTSEA (Fig. 2), this suggests that Cys130 is close to the
peptide binding-site. The lack of eﬀect of IAA and NEM on
ligand binding and, indeed, the lack of reactivity with
Cys130 (Fig. 5) suggests a degree of speciﬁcity in the reaction
of MTSEA with Cys130 or that this residue is not readily
accessible to all reagents.
To further examine the nature of this speciﬁcity, we tested
the eﬀects of other MTS reagents on ligand binding. We found
that the positively charged analogue, MTSPA, which is just
one carbon atom longer than MTSEA, had no eﬀect on ligand
binding and that it did not react with Cys130 (Fig. 5). The neg-
atively charged analogue, MTSES, similarly had no eﬀect onligand binding and did not react with Cys130. Also, as
indicated earlier, the uncharged, more conventional, cysteine-
reactive reagents, NEM and IAA, behaved similarly.
We speculate that the unique eﬀect of MTSEA on the MC4
receptor resides in an ionic interaction of the positively
charged amine group on MTSEA and the negatively charged
acidic residues, Asp126 and Asp122, respectively, one and
two a-helical turns away from Cys130. These three residues
are stacked upon each other down one face of TM3 that lines
the ligand-binding crevice (Fig. 6). This is similar to sugges-
tions made for the D2 receptor in which the positive charge
on MTSEA is thought to bind to an aspartate residue one heli-
cal turn away from the modiﬁed cysteine in TM3 [19]. The
aspartic acid residues Asp126 and Asp122 in the MC4 receptor
are thought to make a crucial ionic interaction with the posi-
tively charged arginine side-chain in core position 8 of a-
MSH based ligands [11]. Thus, the inhibitory action of
MTSEA at the MC4 receptor may be explained by its positive
charge occupying a position crucial to ligand binding, a posi-
tion normally occupied by a positive charge on peptide ligands.
In our modelling of the TM regions of the MC4 receptor, in
Fig. 6. Molecular model of the transmembrane helices of the human MC4 receptor depicting the amino acid residues in TM3 involved in
interaction with MTSEA. The model was built as described in Section 2 using the three-dimensional structure of rhodopsin as a template. (A)
Molecular model of the human MC4 receptor as viewed from an extracellular position perpendicular to the plane of the plasma membrane. The
model was built upon the known structure of bovine rhodopsin [25]. The a-helical backbone structure of the seven transmembrane helices is
shown in various shades of grey and the side-chains of Cys130 (yellow), Asp126 (red) and Asp122 (red) in TM3 are highlighted. (B) A close-up of
part of the model depicting the most extracellular region of TM3. Here, the view is side-on and shows the ‘‘stacked’’ nature of the side-chains of
Cys130, Asp126 and Asp122 down one face of the helix. Cys130 is shown following modiﬁcation by MTSEA (coloured green). (C) A schematic
representation of the model shown in (B).
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it is clear that the positive charge on the modiﬁed side-chain
can only reach as far as the side-chain of Asp126 and thus un-
likely to interact with Asp122. Thus, neutralising only the
charge on Asp126 is suﬃcient to block ligand binding.
For the positively charged MTSPA, which does not bind to
Cys130, it may be that, being one carbon atom longer, it is too
bulky to bind in this region. Alternatively, the reactive meth-
ane thiosulphonate group of MTSPA may not be correctly ori-
entated for the reaction with the side-chain of Cys130. MTSES
had no eﬀect on ligand binding since, being negatively charged,
it is likely to be excluded from the negatively charged region of
TM3. NEM and IAA, both being uncharged and relatively
bulky, are likely to experience no electrostatic attraction to
the charged region of TM3 and steric hindrance may also pre-
vent access to the side-chain of Cys130. Thus, treatment with
these cysteine-reactive reagents leaves Cys130 untouched and
therefore free to react upon a further treatment with MTSEA
(Fig. 5).
In summary, we have demonstrated for the ﬁrst time that
treatment of the human MC4 receptor with the cysteine-
modifying reagent, MTSEA, prevents the binding of agonist
and antagonist ligands and identiﬁed the site of modiﬁcation
as Cys130 in TM3. This indicates the proximity of Cys130 to
the ligand binding-site. Although the residue itself is not cru-
cial for ligand binding, nevertheless, there may well be a cavity
that allows correct docking of the ligand in this region. Thus,
further analysis of this TM region with other probes may help
in an appreciation of the size and depth of the binding pocket.Acknowledgements: This project was supported by the Wellcome Trust
and previously by Knoll Pharmaceuticals (Nottingham). We thank
Mr. John Sinﬁeld for help with Fig. 3.References
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